FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Composition |
| Id | Composition-370512.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Composition 370512
version: 10; Last updated: 2025-10-21 11:07:38+0000; Language: en
Profile: ParticipantFlowReport
Artifact Description:
Example for EBMonFHIR IG
ArtifactPublicationStatus: Active
url: https://fevir.net/resources/Composition/370512
identifier: FEvIR Object Identifier/370512, FEvIR Linking Identifier/NCT03640312-participant-flow-report
status: Final
type: Participant Flow Report
date: 2025-10-21 11:07:38+0000
author: Joanne Dehnbostel
title: Participant Flow Report for QUARTET USA Trial
custodian: Computable Publishing LLC
relatesTo
type: Cite As
target:
Participant Flow Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370512. Revised 2025-10-21. Available at: https://fevir.net/resources/Composition/370512. Computable resource at: https://fevir.net/resources/Composition/370512#json.
relatesTo
type: Derived From
Generated Narrative: Group #ScreenedGroup
name: Group Screened for Participation for QUARTET USA Trial
description:
Potentially eligible patients screened for participation in the QUARTET USA Trial
type: Person
membership: Enumerated
quantity: 120
Generated Narrative: Group #FG000
Profiles: ComparatorGroup, ExposureGroup, StudyGroup
name: NCT03640312 Flow Group QUARTET LDQT
description:
Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
type: Person
membership: Enumerated
quantity: 32
Characteristics
Code Value[x] Exclude Research Study from which this is a flow group NCT03640312 false
Generated Narrative: Group #FG001
name: NCT03640312 Flow Group Candesartan
description:
Patients randomized to the comparison arm took a once daily 8mg candesartan.
Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
type: Person
membership: Enumerated
quantity: 30
Characteristics
Code Value[x] Exclude Research Study from which this is a flow group NCT03640312 false
Generated Narrative: Evidence #ExcludedCount
title: Excluded from QUARTET USA Trial
status: Active
variableDefinition
description:
Screened for Participation
variableRole: Population
observed: Screened for Participation
variableDefinition
description:
Excluded
variableRole: Outcome
observed: Excluded
Statistics
StatisticType Quantity count 58
Generated Narrative: Evidence #ReasonsForExclusion
title: Reasons for exclusion from QUARTET USA Trial
status: Active
variableDefinition
description:
Screened for Participation
variableRole: Population
observed: Screened for Participation
variableDefinition
description:
Reasons for exclusion from QUARTET USA Trial
variableRole: Outcome
statistic
statisticType: count
category: Not meeting inclusion criteria
quantity: 56
statistic
statisticType: count
category: Other reasons: "no-shows" for randomization
quantity: 2
Generated Narrative: Evidence #NCT03640312-flow-milestone-0-Overall-Study-group-FG000
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-0-Overall-Study-group-FG000
title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: QUARTET LDQT
variableDefinition
variableRole: Outcome
observed: STARTED at Overall Study
Statistics
StatisticType Quantity Count 32
Generated Narrative: Evidence #NCT03640312-flow-milestone-0-Overall-Study-group-FG001
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-0-Overall-Study-group-FG001
title: ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: Candesartan
variableDefinition
variableRole: Outcome
observed: STARTED at Overall Study
Statistics
StatisticType Quantity Count 30
Generated Narrative: Evidence #NCT03640312-flow-milestone-1-Overall-Study-group-FG000
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-1-Overall-Study-group-FG000
title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: QUARTET LDQT
variableDefinition
variableRole: Outcome
observed: 6 Week Follow Up at Overall Study
Statistics
StatisticType Quantity Count 32
Generated Narrative: Evidence #NCT03640312-flow-milestone-1-Overall-Study-group-FG001
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-1-Overall-Study-group-FG001
title: ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: Candesartan
variableDefinition
variableRole: Outcome
observed: 6 Week Follow Up at Overall Study
Statistics
StatisticType Quantity Count 28
Generated Narrative: Evidence #NCT03640312-flow-milestone-2-Overall-Study-group-FG000
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-2-Overall-Study-group-FG000
title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: QUARTET LDQT
variableDefinition
variableRole: Outcome
observed: COMPLETED at Overall Study
Statistics
StatisticType Quantity Count 29
Generated Narrative: Evidence #NCT03640312-flow-milestone-2-Overall-Study-group-FG001
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-2-Overall-Study-group-FG001
title: ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: Candesartan
variableDefinition
variableRole: Outcome
observed: COMPLETED at Overall Study
Statistics
StatisticType Quantity Count 24
Generated Narrative: Evidence #NCT03640312-flow-milestone-3-Overall-Study-group-FG000
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-3-Overall-Study-group-FG000
title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: QUARTET LDQT
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Overall Study
Statistics
StatisticType Quantity Count 3
Generated Narrative: Evidence #NCT03640312-flow-milestone-3-Overall-Study-group-FG001
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-3-Overall-Study-group-FG001
title: ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: Candesartan
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Overall Study
Statistics
StatisticType Quantity Count 6
Generated Narrative: Evidence #NCT03640312-flow-reason-Overall-Study-group-FG000
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-reason-Overall-Study-group-FG000
title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: QUARTET LDQT
variableDefinition
variableRole: Outcome
observed: Reasons for withdraw at Overall Study
Statistics
StatisticType Category Quantity Count Lost to Follow-up 3
Generated Narrative: Evidence #NCT03640312-flow-reason-Overall-Study-group-FG001
Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03640312-flow-reason-Overall-Study-group-FG001
title: ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
Code Value[x] Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition
variableRole: Population
observed: Candesartan
variableDefinition
variableRole: Outcome
observed: Reasons for withdraw at Overall Study
Statistics
StatisticType Category Quantity Count Lost to Follow-up 6
{
"resourceType": "Composition",
"id": "370512",
"meta": {
"versionId": "10",
"lastUpdated": "2025-10-21T11:07:38.408Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"
]
},
"language": "en",
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"contained": [
{
"resourceType": "Group",
"id": "ScreenedGroup",
"name": "Group Screened for Participation for QUARTET USA Trial",
"description": "Potentially eligible patients screened for participation in the QUARTET USA Trial",
"type": "person",
"membership": "enumerated",
"quantity": 120
},
{
"resourceType": "Group",
"id": "FG000",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-group",
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group",
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-group"
]
},
"name": "NCT03640312 Flow Group QUARTET LDQT",
"description": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.",
"type": "person",
"membership": "enumerated",
"quantity": 32,
"characteristic": [
{
"code": {
"text": "Research Study from which this is a flow group"
},
"valueReference": {
"display": "NCT03640312"
},
"exclude": false
}
]
},
{
"resourceType": "Group",
"id": "FG001",
"name": "NCT03640312 Flow Group Candesartan",
"description": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.",
"type": "person",
"membership": "enumerated",
"quantity": 30,
"characteristic": [
{
"code": {
"text": "Research Study from which this is a flow group"
},
"valueReference": {
"display": "NCT03640312"
},
"exclude": false
}
]
},
{
"resourceType": "Evidence",
"id": "ExcludedCount",
"title": "Excluded from QUARTET USA Trial",
"status": "active",
"variableDefinition": [
{
"description": "Screened for Participation",
"variableRole": "population",
"observed": {
"reference": "#ScreenedGroup",
"type": "Group",
"display": "Screened for Participation"
}
},
{
"description": "Excluded",
"variableRole": "outcome",
"observed": {
"type": "EvidenceVariable",
"display": "Excluded"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "count"
}
]
},
"quantity": {
"value": 58
}
}
]
},
{
"resourceType": "Evidence",
"id": "ReasonsForExclusion",
"title": "Reasons for exclusion from QUARTET USA Trial",
"status": "active",
"variableDefinition": [
{
"description": "Screened for Participation",
"variableRole": "population",
"observed": {
"reference": "#ScreenedGroup",
"type": "Group",
"display": "Screened for Participation"
}
},
{
"description": "Reasons for exclusion from QUARTET USA Trial",
"variableRole": "outcome",
"observed": {
"reference": "EvidenceVariable/372461",
"type": "EvidenceVariable",
"display": "Reasons for exclusion from QUARTET USA Trial"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "count"
}
]
},
"category": {
"text": "Not meeting inclusion criteria"
},
"quantity": {
"value": 56
}
},
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "count"
}
]
},
"category": {
"text": "Other reasons: \"no-shows\" for randomization"
},
"quantity": {
"value": 2
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-0-Overall-Study-group-FG000",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-0-Overall-Study-group-FG000",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG000",
"type": "Group",
"display": "QUARTET LDQT"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "STARTED at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 32
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-0-Overall-Study-group-FG001",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-0-Overall-Study-group-FG001",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG001",
"type": "Group",
"display": "Candesartan"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "STARTED at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 30
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-1-Overall-Study-group-FG000",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-1-Overall-Study-group-FG000",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG000",
"type": "Group",
"display": "QUARTET LDQT"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "6 Week Follow Up at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 32
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-1-Overall-Study-group-FG001",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-1-Overall-Study-group-FG001",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG001",
"type": "Group",
"display": "Candesartan"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "6 Week Follow Up at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 28
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-2-Overall-Study-group-FG000",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-2-Overall-Study-group-FG000",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG000",
"type": "Group",
"display": "QUARTET LDQT"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "COMPLETED at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 29
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-2-Overall-Study-group-FG001",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-2-Overall-Study-group-FG001",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG001",
"type": "Group",
"display": "Candesartan"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "COMPLETED at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 24
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-3-Overall-Study-group-FG000",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-3-Overall-Study-group-FG000",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG000",
"type": "Group",
"display": "QUARTET LDQT"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "NOT COMPLETED at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 3
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-milestone-3-Overall-Study-group-FG001",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-milestone-3-Overall-Study-group-FG001",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG001",
"type": "Group",
"display": "Candesartan"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "NOT COMPLETED at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"quantity": {
"value": 6
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-reason-Overall-Study-group-FG000",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-reason-Overall-Study-group-FG000",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG000",
"type": "Group",
"display": "QUARTET LDQT"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "Reasons for withdraw at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"category": {
"text": "Lost to Follow-up"
},
"quantity": {
"value": 3
}
}
]
},
{
"resourceType": "Evidence",
"id": "NCT03640312-flow-reason-Overall-Study-group-FG001",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier": [
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-flow-reason-Overall-Study-group-FG001",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowEvidence",
"display": "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "#FG001",
"type": "Group",
"display": "Candesartan"
}
},
{
"variableRole": "outcome",
"observed": {
"display": "Reasons for withdraw at Overall Study"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000047",
"display": "Count"
}
]
},
"category": {
"text": "Lost to Follow-up"
},
"quantity": {
"value": 6
}
}
]
}
],
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-description",
"valueMarkdown": "Example for EBMonFHIR IG"
},
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Composition/370512",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "370512",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-participant-flow-report",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"status": "final",
"type": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ParticipantFlowReport",
"display": "ParticipantFlowReport"
}
],
"text": "Participant Flow Report"
},
"date": "2025-10-21T11:07:38.408Z",
"author": [
{
"display": "Joanne Dehnbostel"
}
],
"title": "Participant Flow Report for QUARTET USA Trial",
"custodian": {
"reference": "Organization/118079",
"type": "Organization",
"display": "Computable Publishing LLC"
},
"relatesTo": [
{
"type": "cite-as",
"targetMarkdown": "Participant Flow Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370512. Revised 2025-10-21. Available at: https://fevir.net/resources/Composition/370512. Computable resource at: https://fevir.net/resources/Composition/370512#json."
},
{
"type": "derived-from",
"targetReference": {
"reference": "Composition/370502",
"type": "Composition",
"display": "Participant Flow Report for NCT03640312"
}
}
],
"section": [
{
"title": "Excluded",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"type": "EvidenceVariable",
"display": "Excluded"
},
"entry": [
{
"reference": "#ExcludedCount",
"type": "Evidence",
"display": "Excluded from QUARTET USA Trial"
}
]
},
{
"title": "Reasons for exclusion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/372461",
"type": "EvidenceVariable",
"display": "Reasons for exclusion from QUARTET USA Trial"
},
"entry": [
{
"reference": "#ReasonsForExclusion",
"type": "Evidence",
"display": "Reasons for exclusion from QUARTET USA Trial"
}
]
},
{
"title": "Flow PreAssignment Details",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "participant-flow-details",
"display": "Participant Flow Details"
}
],
"text": "FlowPreAssignmentDetails"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">NA - all enrolled participants were randomized.</div>"
}
},
{
"title": "Flow Recruitment Details",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "participant-flow-details",
"display": "Participant Flow Details"
}
],
"text": "FlowRecruitmentDetails"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">120 were consented and assessed for eligibility. 58 were excluded for not meeting either inclusion or exclusion criteria, declining participation, or not showing up for randomization visits. Thus, these 58 individuals were not randomized, and 62 participants were randomized</div>"
}
},
{
"title": "Flow Group List",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "groups",
"display": "Groups"
}
],
"text": "FlowGroupList"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">QUARTET LDQT, Candesartan</div>"
},
"entry": [
{
"reference": "#ScreenedGroup",
"type": "Group",
"display": "Screened for Participation"
},
{
"reference": "#FG000",
"type": "Group",
"display": "QUARTET LDQT"
},
{
"reference": "#FG001",
"type": "Group",
"display": "Candesartan"
}
]
},
{
"title": "STARTED at Overall Study",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
],
"text": "Participant Flow Results"
},
"focus": {
"display": "STARTED at Overall Study"
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry": [
{
"reference": "#NCT03640312-flow-milestone-0-Overall-Study-group-FG000",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study"
},
{
"reference": "#NCT03640312-flow-milestone-0-Overall-Study-group-FG001",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study"
}
]
},
{
"title": "6 Week Follow Up at Overall Study",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
],
"text": "Participant Flow Results"
},
"focus": {
"display": "6 Week Follow Up at Overall Study"
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry": [
{
"reference": "#NCT03640312-flow-milestone-1-Overall-Study-group-FG000",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study"
},
{
"reference": "#NCT03640312-flow-milestone-1-Overall-Study-group-FG001",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study"
}
]
},
{
"title": "COMPLETED at Overall Study",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
],
"text": "Participant Flow Results"
},
"focus": {
"display": "COMPLETED at Overall Study"
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry": [
{
"reference": "#NCT03640312-flow-milestone-2-Overall-Study-group-FG000",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study"
},
{
"reference": "#NCT03640312-flow-milestone-2-Overall-Study-group-FG001",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study"
}
]
},
{
"title": "NOT COMPLETED at Overall Study",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
],
"text": "Participant Flow Results"
},
"focus": {
"display": "NOT COMPLETED at Overall Study"
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry": [
{
"reference": "#NCT03640312-flow-milestone-3-Overall-Study-group-FG000",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study"
},
{
"reference": "#NCT03640312-flow-milestone-3-Overall-Study-group-FG001",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study"
}
]
},
{
"title": "Reasons for withdraw at Overall Study",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
],
"text": "Participant Flow Results"
},
"focus": {
"display": "Reasons for withdraw at Overall Study"
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry": [
{
"reference": "#NCT03640312-flow-reason-Overall-Study-group-FG000",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study"
},
{
"reference": "#NCT03640312-flow-reason-Overall-Study-group-FG001",
"type": "Evidence",
"display": "ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study"
}
]
}
]
}